Ryan G, Latimer K M, Juniper E F, Roberts R S, Hargreave F E
J Allergy Clin Immunol. 1985 Jan;75(1 Pt 1):25-30. doi: 10.1016/0091-6749(85)90007-7.
We investigated the possibility that corticosteroids can reduce bronchial responsiveness to histamine by mechanisms other than change in airway caliber. Ten adult asthmatic subjects were selected because their symptoms were controlled by bronchodilators alone, they had no recent respiratory infection or allergen exposure that might have temporarily altered responsiveness, their spirometry was more than 70% predicted, and they had a range of histamine bronchial hyperresponsiveness. They received, in random order and double-blind manner, beclomethasone dipropionate (400 micrograms daily) or placebo for 4 wk and then, after a 2-week washout period, they crossed over to the other treatment for 4 wk. Treatment with beclomethasone induced a small but significant reduction in bronchial responsiveness to histamine (p = 0.014). Although the improvement was too small to be considered of clinical significance, its importance lies in the mechanisms by which it was produced. Part of the improvement was related to improvement in airway caliber, but, even when the data was adjusted for this, there was still a significant difference between beclomethasone and placebo treatment (p = 0.018). The results suggest that regular treatment with corticosteroids can alter bronchial responsiveness through mechanisms other than change in airway caliber.
我们研究了皮质类固醇是否可通过气道口径变化以外的机制降低支气管对组胺的反应性。选择了10名成年哮喘患者,原因是他们的症状仅通过支气管扩张剂就能得到控制,近期无可能暂时改变反应性的呼吸道感染或过敏原接触史,其肺量计测定值超过预测值的70%,且具有一定范围的组胺支气管高反应性。他们以随机顺序和双盲方式接受丙酸倍氯米松(每日400微克)或安慰剂治疗4周,然后在经过2周的洗脱期后,交叉接受另一种治疗4周。丙酸倍氯米松治疗使支气管对组胺的反应性出现了虽小但显著的降低(p = 0.014)。尽管改善程度过小,不具有临床意义,但其重要性在于其产生的机制。部分改善与气道口径的改善有关,但即便针对此对数据进行校正后,丙酸倍氯米松治疗与安慰剂治疗之间仍存在显著差异(p = 0.018)。结果表明,皮质类固醇的常规治疗可通过气道口径变化以外的机制改变支气管反应性。